Gilead presents real-world evidence reinforcing the use of Biktarvy® for the treatment of people living with HIV with a range of comorbidities

Back to the "HIV and Co-Infections News" list
  • HIV Treatment
October 24, 2022
  • New clinical outcomes from BICSTaR study show sustained impact of Biktarvy for people with HIV
  • Five-year data from studies 1489 and 1490 solidify the robust and durable efficacy and safety profile of Biktarvy

Read the full press release here.

 

Source : Gilead Sciences, Inc.

Related HIV and Co-Infections News

See all related HIV and Co-Infections News

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.